{"id":75050,"date":"2026-11-20T23:08:31","date_gmt":"2026-11-21T03:08:31","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/fda-rejects-capricors-duchenne-therapy-over-data-integrity-hegseth-limits-canada-defense-ties\/75050\/"},"modified":"2026-11-20T23:08:31","modified_gmt":"2026-11-21T03:08:31","slug":"fda-rejects-capricors-duchenne-therapy-over-data-integrity-hegseth-limits-canada-defense-ties","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/fda-rejects-capricors-duchenne-therapy-over-data-integrity-hegseth-limits-canada-defense-ties\/75050\/","title":{"rendered":"FDA Rejects Capricor\u2019s Duchenne Therapy Over Data Integrity; Hegseth Limits Canada Defense Ties"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Capricor Therapeutics (<a href=\"\/stock\/CAPR\">CAPR<\/a>) shares plummeted over 80%<\/strong> in extended trading after the <strong>FDA rejected its BLA for Deramiocel<\/strong>, citing &quot;serious deficiencies&quot; in clinical trial conduct.<\/li>\n<li><strong>Defense Secretary Pete Hegseth<\/strong> issued a classified directive <strong>restricting U.S. defense cooperation with Canada<\/strong>, a move described by officials as a &quot;slap in the face&quot; to the long-standing ally.<\/li>\n<li><strong>The FDA identified &quot;unreliable&quot; data in the HOPE-3 study<\/strong> that cannot be rectified post-trial, involving unauthorized changes to statistical analyses and violations of trial blinding.<\/li>\n<li><strong>U.S. intelligence sharing and NORAD collaboration<\/strong> are reportedly excluded from the new defense restrictions, though broader military ties face significant curtailment.<\/li>\n<li><strong>Capricor maintains $198.5 million in cash<\/strong> as of late 2026, which it claims provides a 12-month runway despite the massive regulatory setback.<\/li>\n<\/ul>\n<h2>FDA Issues Complete Response Letter to Capricor Therapeutics<\/h2>\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has officially rejected the Biologics License Application (BLA) for <strong>Deramiocel<\/strong>, an investigational cell therapy developed by Capricor Therapeutics (<a href=\"\/stock\/CAPR\">CAPR<\/a>) for <strong>Duchenne muscular dystrophy (DMD)<\/strong>. In a rare public statement accompanying the <strong>Complete Response Letter (CRL)<\/strong>, the regulator stated that the evidence provided did not meet the &quot;substantial evidence of effectiveness&quot; required for approval.<\/p>\n<p>The rejection was primarily driven by <strong>serious data integrity issues<\/strong> discovered during a Bioresearch Monitoring (BIMO) inspection of the <strong>HOPE-3 study<\/strong>. The FDA noted that Capricor made <strong>unauthorized changes to statistical analysis plans<\/strong> after the study began and violated <strong>trial blinding procedures<\/strong>, rendering the resulting data unreliable and &quot;incapable of post hoc remediation.&quot;<\/p>\n<p>Following the news, <strong>Capricor (<a href=\"\/stock\/CAPR\">CAPR<\/a>)<\/strong> shares crashed by more than <strong>80% in after-hours trading<\/strong>, falling from a daily high of $8.94 to approximately $1.48. While CEO <strong>Linda Marb\u00e1n<\/strong> expressed deep disappointment and stood by the &quot;rigor&quot; of the clinical program, the company is now forced to review its operating costs and evaluate the future of its lead experimental asset.<\/p>\n<h2>Hegseth Memo Escalates Tensions with Canada<\/h2>\n<p>In a separate geopolitical development, <strong>Defense Secretary Pete Hegseth<\/strong> has imposed new restrictions on the <strong>U.S.-Canada defense relationship<\/strong> via a classified memo. The directive marks a significant escalation in the ongoing friction between the <strong>Trump administration<\/strong> and Ottawa, coming on the heels of repeated threats regarding trade and territorial annexation.<\/p>\n<p>While the specific nature of the restrictions remains classified, a <strong>Pentagon spokesman<\/strong> clarified that the directive will not impact <strong>defense intelligence sharing<\/strong> or collaboration through <strong>NATO<\/strong> and <strong>NORAD<\/strong>. Instead, the Pentagon is reportedly &quot;prioritizing opportunities&quot; that specifically advance &quot;tangible U.S. defense objectives&quot; and pressure Canada to meet its <strong>NATO spending obligations<\/strong>.<\/p>\n<p>The move has been met with concern from defense officials, who warn that curtailing interactions between the two militaries could damage a foundational security partnership. The <strong>Canadian embassy<\/strong> has yet to issue a formal comment, though the restrictions are widely viewed by analysts as a strategic &quot;slap in the face&quot; intended to force concessions from Prime Minister <strong>Mark Carney\u2019s<\/strong> government.<\/p>\n<h2>Market Implications and Data Integrity Scrutiny<\/h2>\n<p>The dual blow of clinical trial failures and shifting geopolitical alliances has introduced fresh volatility into the biotechnology and defense sectors. The <strong>FDA\u2019s<\/strong> aggressive stance on the <strong>HOPE-3 study<\/strong> highlights a broader regulatory trend of increased scrutiny toward <strong>data integrity<\/strong>, particularly for therapies targeting rare diseases where evidentiary standards are often debated.<\/p>\n<p>For <strong>Capricor (<a href=\"\/stock\/CAPR%5D\">CAPR<\/a><\/strong>, the path forward remains highly uncertain as the agency indicated that the identified trial deficiencies cannot be fixed retrospectively. Investors are now focused on the company&#39;s remaining <strong>$198.5 million cash reserve<\/strong> and whether a new, more rigorous Phase 3 trial will be required to salvage the Deramiocel program.<\/p>\n<p>Meanwhile, the <strong>Hegseth directive<\/strong> may signal a shift in how the U.S. manages bilateral defense contracts and joint procurement programs with Canada. <em>Market participants in the defense sector are closely watching for any signs that these restrictions could extend to industrial cooperation or cross-border supply chains for critical military hardware.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Capricor Therapeutics (CAPR) shares plummeted over 80% in extended trading after the FDA rejected its BLA for Deramiocel, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[24264,1676,24265,4100,5833,7510,9631,12797,24261,24262,24263],"class_list":["post-75050","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-hope-3-study","tag-dmd","tag-bimo","tag-crl","tag-fda","tag-us-canada-relations","tag-bla","tag-pete-hegseth","tag-capricor-therapeutics","tag-capr-stock-capr","tag-duchenne-muscular-dystrophy"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/75050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=75050"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/75050\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=75050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=75050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=75050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}